The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?
Open accessAbstract
Background Although the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score is recommended by both American and European guidelines for stroke risk stratification in atrial fibrillation (AF), the treatment recommendations for a CHA2DS2-VASc score of 1 are less clear.Objectives This study aimed to investigate the risk of ischemic stroke in patients with a single additional stroke risk factor (i.e., CHA2DS2-VASc score = 1 [males] or 2 [females]) and the impact of different component risk factors.Methods We used the National Health Insurance Research Database in Taiwan. Among 186,570 AF patients not on antiplatelet or anticoagulant therapy, we evaluated males with a CHA2DS2-VASc score of 1 and females with a CHA2DS2-VASc score of 2. The clinical endpoint was the occurrence of ischemic stroke.Results Among 12,935 male AF patients with a CHA2DS2-VASc score of 1, 1,858 patients (14.4%) experienced ischemic stroke during follow-up (5.2 ± 4.3 years), with an annual stroke rate of 2.75%. Ischemic stroke risk ranged from 1.96%/year for men with vascular disease to 3.50%/year for those 65 to 74 years of age. For 7,900 females with AF and a CHA2DS2-VASc score of 2, 14.9% experienced ischemic stroke for an annual stroke rate of 2.55%. Ischemic stroke risk increased from 1.91%/year for women with hypertension to 3.34%/year for those 65 to 74 years of age.Conclusions Not all risk factors in CHA2DS2-VASc score carry an equal risk, with age 65 to 74 years associated with the highest stroke rate. Oral anticoagulation should be considered for AF patients with 1 additional stroke risk factor given their high risk of ischemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In many of these patients, anticoagulation seems to provide a clinical benefit.[371][372][373][374][375]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [372]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,823
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–257 of 257
Rare variant of Remkheld syndrome
Анатольевна, Ч. С., Nasytko, A. D., & Shavkuta, G. V. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-196-12-147-153 · Cited by 3
Şimşek, E. Ç., Şekerci, S. S., Gücün, M., Tanrıkulu, S., Ahi, E. D., Ozdengulsun, B., & Aras, D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051758 · Cited by 2
When are the cardiovascular and stroke risks too high? Pharmacotherapy for stroke prophylaxis
Gómez‐Outes, A., Suárez‐Gea, M. L., & García‐Pinilla, J. M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1511703 · Cited by 2
“With the same moderate risk score (1 in men and 2 in women), patients aged 65–74 years or with DM requiring treatment with insulin as the sole risk factor, have a higher risk of stroke than those who present stable HF, controlled hypertension, or vascular disease as the only risk factors [52].”
BackgroundNon-vitamin K antagonist oral anticoagulants and sport
Romano, S., Salustri, E., Robles, A. G., Calò, L., Penco, M., & Sciarra, L. (2020) · Minerva Cardioangiologica · doi:10.23736/s0026-4725.20.05177-4 · Cited by 2
Li, J., Hidru, T. H., Yang, X., Yang, Y., Liu, F., Lou, Z., Guan, X., Wu, S., & Xia, Y. (2021) · International Heart Journal · doi:10.1536/ihj.20-611 · Cited by 2
Druzhilov, М. A., & Kuznetsova, Т. Y. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5522 · Cited by 2
Yang, Y., Xu, F., Tong, J., Cai, L., Jiang, W., Sheng, X., Pan, Y., Jiang, J., Zhang, J., Jiang, D., et al. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6807-9 · Cited by 3
Татаринцева, З. Г., Kosmacheva, E. D., & Porkhanov, V. A. (2018) · Kardiologiia · doi:10.18087/cardio.2490 · Cited by 2
Age, Ethnicity, and Stroke Risk in Patients With Atrial Fibrillation
Savino, J. A., & Halperin, J. L. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.003 · Cited by 2
Kim, D., Lee, Y. S., Shim, J., Park, J., Park, J., Oh, I., Kang, K., Choi, E., Park, K., Park, H., et al. (2025) · Heart Rhythm O2 · doi:10.1016/j.hroo.2025.12.008 · Cited by 1
“29 These findings highlight the limitations of the CHA 2 DS 2 -VASc score in accurately stratifying risk for intermediate-risk patients.”
Liu, J., Zhu, X., Zheng, X., Ren, M., Jing, Y., & Chu, H. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05348-6 · Cited by 1
“This aligns with prior observations that not all factors in the CHA2DS2-VASc score confer equivalent risk due to the variations in both temporal exposure and clinical severity of underlying conditions [29].”
Liu, L., Liu, H., Sun, P., Aa, G., Liu, Y., Zhang, Z., Yang, Q., & Zhou, X. (2026) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296261442055 · Cited by 1
“Asian patients often exhibit a higher intrinsic risk of ischemic stroke than Western counterparts with similar CHA 2 DS 2 -VASc scores 37 and may experience a greater prognostic impact from certain SMurfs like hypertension.”
Ryan, D., Yahav, A., Barnett‐Griness, O., Danon, A., Schliamser, J. E., Auriel, E., & Saliba, W. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.06.028 · Cited by 1
Editor-in-Chief’s Top Picks From 2015: Part One
Fuster, V. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.002 · Cited by 1
Differences in atrial fibrillation management strategies among physicians: A survey based study
Şanlıalp, S. Ç., Türk, U. Ö., Okyay, K., Başaran, Ö., Canpolat, U., & Zoghi, M. (2019) · International Journal of the Cardiovascular Academy · doi:10.4103/ijca.ijca_51_18 · Cited by 1
“[6,15] In this survey, 70% of the physicians accepted the anticoagulant starting limit as CHA2DS2VASc of ≥2 for females, but current guidelines revealed that female gender alone does not appear to increase stroke risk in the absence of other stroke risk factors.[16,17] There are some differences about the risk scoring…”
BackgroundStroke prevention in atrial fibrillation: Where are we now?
Lip, G. Y. H. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.11.002 · Cited by 1
Cardiac Arrhythmias and Pacing 2015: A Selection of Topical Issues
Peinado, R., Ruiz‐Mateas, F., Izquierdo, M., Arana‐Rueda, E., Robledo, M. J. L., Arias, M. A., Jiménez‐Jáimez, J., Rodríguez‐Mañero, M., & Chimeno, J. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.11.005 · Cited by 1
Enfermedad cerebrovascular en mujeres: estado del arte y visión del cardiólogo
Contreras, J., Pérez, O., & Figueroa, N. (2018) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.12.014 · Cited by 1
Артериальная гипертензия и фибрилляция предсердий: опасная «дружба», которую нельзя игнорировать!
Skybchyk, V. А., Бабляк, С. Д., & Matviyenko, Y. (2019) · HYPERTENSION · doi:10.22141/2224-1485.3-4.64-65.2019.177851 · Cited by 1
Aggiornamenti in tema di malattia cerebrovascolare: prevenzione, terapia e riabilitazione
Bandini, G. E. F., Fontanella, A., & Manfellotto, D. (2020) · Italian Journal of Medicine · doi:10.4081/itjm.q.2020.2 · Cited by 1
Andersson, T., & Aspberg, S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.10.075 · Cited by 1
Arnson, Y., Senderey, A. B., Hoshen, M., Reges, O., Balicer, R. D., Alnsasra, H., Leibowitz, M., Tsadok, M. A., & Haim, M. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02618-y · Cited by 1
Physician Estimation of Thrombotic and Bleeding Risks in Atrial Fibrillation: Let’s Talk About Sex
Ding, W. Y., Gupta, D., & Lip, G. Y. H. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.12.011 · Cited by 1
Anticoagulation for Atrial Fibrillation in the Emergency Department or Observation Unit
Bhatt, D. L., & Noll, A. E. (2016) · Contemporary cardiology · doi:10.1007/978-3-319-31386-3_9
Misconceptions and Facts About Atrial
Argulian, F., Conen, D., & Li, D. (2015)
Muscente, F., & Caterina, R. D. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000475
Antithrombotic therapy in patients with atrial fibrillation : the Tasmanian experience
Bista, D. (2016) · UTAS Research Repository · doi:10.25959/23239073
Breitenstein, A., & Steffel, J. (2017) · Praxis · doi:10.1024/1661-8157/a002725
Shu, W., Li, J., Yan, G., Zhang, Y., & Sun, M. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.04.012
“But large studies of Asian populations showed that the incidence of TE complication may be N2% every year in patients with AF and CHA2DS2-VASc Score 1 [2,3].”
BackgroundMakowski, M., & Baj, Z. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.033
“It is striking that these patients according to studies on Asian population have higher risk over 2% as compared to European studies [1,2].”
ResultSingh‐Franco, D., Hale, G. M., & Jacobs, R. J. (2017) · Hospital Practice · doi:10.1080/21548331.2018.1415621
Gilyarov, M. Y., & Константинова, Е. В. (2017) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2017-2-21-31
Potpara, T., Jokić, V., & Mijatovic, Z. (2016) · Srce i krvni sudovi · doi:10.5937/siks1601018p
Risk Stratification in Atrial Fibrillation
Shahid, F., Dzeshka, M. S., Shantsila, E., & Lip, G. Y. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55429-9.00004-2
Anticoagulantes orales en pacientes con fibrilación auricular no valvular y con bajo riesgo
Sabatel-Pérez, F., Akerström, F. O., Arias, M. A., Pachón, M., Puchol, A., & Padial, L. R. (2018) · Medicina Clínica · doi:10.1016/s0025-7753(18)30665-1
Kryukov, N. N., Sayutina, E. V., Осадчук, А. М., & Osadchuk, M. A. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-1-94-102
Image‐based Risk Stratification for Stroke in Atrial Fibrillation
Romero, J. E., Briceno, D. F., Gianni, C., Mohanty, S., Natale, A., Garcia, M. J., & Biase, L. D. (2019) · Wiley eBooks · doi:10.1002/9781119152637.ch43
Allan, V. (2018) · UCL Discovery (University College London)
Bonfanti, L., Lippi, G., Donelli, V., Pigna, F., Saccenti, C., & Cervellin, G. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.04.057
Sulzgruber, P., & Niessner, A. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz040
Hammer, A., Schnaubelt, S., Niessner, A., & Sulzgruber, P. (2020) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa176
“In this regard, the patient’s age and presence of Type II diabetes mellitus were the most prominent isolated risk factors for stroke.(11,12) Also the type (atrial flutter vs.”
BackgroundEditor-in-Chief’s Top Picks From 2015: Part Two
Fuster, V. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.003
Capiau, A., Grymonprez, M., Backer, T. L. M. D., Gevaert, S., Boussery, K., & Lahousse, L. (2021) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.77.21.107
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch10
Hanna, E. B. (2017) · Wiley eBooks · doi:10.1002/9781119233503.ch10
(2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.10.032
Fibrilación auricular: fisiopatología, factores de riesgo y rol de la anticoagulación oral
Corrales-Santander, H. R., Cuellar-Lobo, M., Trocha-Ramos, A., Castillo-Eguis, S., Rios-Díaz, E., & Morantes-Caballero, J. A. (2022) · Revista Ciencias Biomédicas · doi:10.32997/rcb-2022-3704
Raposeiras‐Roubín, S., Chao, T., Abu‐Assi, E., Chan, Y., Bermúdez, I. G., Liao, J., Kuo, L., Ferreiro, R. G., & Íñiguez, A. (2024) · medRxiv · doi:10.1101/2024.06.20.24309269
Rethinking Stroke Prevention in Atrial Fibrillation: One Size Does not Fit All
Papakonstantinou, P. Ε., & Lip, G. Y. H. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16580
“Both patients have a CHA 2 DS 2 ‐ VA(Sc) score of 1, but they exhibit a completely different risk of ischemic stroke [8].”
Sex and gender differences in cardiovascular diseases
Raparelli, V., Proietti, M., Romiti, G. F., & Basili, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27398-8.00008-3
Fibrilación y flúter auricular
Fraile, P. Z., Castellano, N. P., García-Bello, E., Ferrer, J. J. G., & Villacastín, J. P. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.09.010
Romiti, G. F., Corica, B., Mei, D. A., Bisson, A., Boriani, G., Olshansky, B., Chao, T.-F., Huisman, M. V., Proietti, M., & Lip, G. Y. H. (2024) · Figshare · doi:10.6084/m9.figshare.25566183
Tsai, C.-T., Chan, Y., Liao, J., Chen, T.-J., Lip, G. Y. H., Chen, S.-A., & Chao, T.-F. (2024) · Figshare · doi:10.6084/m9.figshare.25397454
Tsai, C.-T., Chan, Y., Liao, J., Chen, T.-J., Lip, G. Y. H., Chen, S.-A., & Chao, T.-F. (2024) · Figshare · doi:10.6084/m9.figshare.25397734
Hailesilase, G. G., Atsbha, G. H., Gebrezgabiher, H. A., & Kidane, A. M. (2026) · eNeurologicalSci · doi:10.1016/j.ensci.2026.100610
“…scores, the patients were diagnosed to have the comorbidities such as hypertension, diabetes mellitus and heart failure only if the diseases were discharge diagnoses or confirmed at least twice in an outpatient department or when the patients were on medication for these specific diseases [19,23].”
Gao, T., Zhang, X., Ma, T., Li, M., Hou, B., Lin, Z., Cai, J., Huang, S., Liu, X., Zhao, Y., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1725168
Chao, T., Lip, G. Y. H., Chan, Y., Lee, S., Li, M., Kim, D., Kuo, L., Okumura, K., Tse, H., Choi, E., et al. (2026) · Journal of Arrhythmia · doi:10.1002/joa3.70491
Metadata
- Authors
- Chao, T.-F., Liu, C.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Tuan, T.-C., Chen, T.-J., Lip, G. Y. H., & Chen, S.-A.
- Affiliations
- Taipei Veterans General Hospital (TW)
- Birmingham City Hospital (GB)
- Corresponding author
- Chen, Shih-Ann
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 65
- Issue
- 7
- Pages
- 635-642
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2022880742
- Cited by
- 258
- References
- 43
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 16 · 2023: 8 · 2022: 9 · 2021: 18 · 2020: 24 · 2019: 30 · 2018: 40 · 2017: 28 · 2016: 46 · 2015: 24
- FWCI
- 33.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- National Science Council (NSC98-2410-H-010-003-MY2)
- Taipei Veterans General Hospital (V100D-002-3, V101D-001-2, V102B-025, V99A-153, V99C1-140)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- atrial fibrillation, CHA2DS2-VASc score, oral anticoagulation, ischemic stroke risk, stroke risk stratification, sex differences, hypertension, vascular disease, diabetes mellitus, congestive heart failure
- MeSH terms
- Administration, Oral, Age Factors, Aged, Anticoagulants, Atrial Fibrillation, Ischemic Attack, Transient, Female, Humans, Hypertension, Male, Middle Aged, Retrospective Studies, Risk Factors, Sex Factors, Taiwan, Risk Assessment, Stroke, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
